Striatal cell-type–specific molecular signatures reveal potential therapeutic targets in a model of dystonia.
Published in Neurobiology of Disease, 2025
Recommended citation: Roman KM, Dinasarapu AR , Cherian S, Fan X, Donsante Y, Aravind N, Chan C,S, Jinnah HA, Hess EJ. Striatal cell-type–specific molecular signatures reveal potential therapeutic targets in a model of dystonia Neurobiology of Disease,(2025) https://doi.org/10.1016/j.nbd.2025.106981
Abnormal dopamine neurotransmission and striatal dysfunction is implicated in many forms of dystonia, yet the underlying molecular processes remain unknown. Here, we identified thousands of dysregulated genes within striatal spiny projection neuron (SPN) subtypes in a genetic mouse model of DOPA-responsive dystonia (DRD), which is caused by gene defects that reduce dopamine neurotransmission.